Key publications relevant to our platform and programs.
CB derived, optimized affinity CD38 CAR-NK cells with CD38 KO show promising in-vivo activity in a Multiple Myeloma model
S Brophy et al.
Event: IMS 2022
Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor natural killer cells
Gurny M, O’Reilly E, Corcoran S, Brophy S, Krawczyk J, Otto N.M, Hermanson D.L, Childs RW, Szegezdi E, O’Dwyer ME
Cytotherapy. 2022 Aug 29: S1465-3249(22)00739-3.doi. 10.1016/j.jcyt.2022.07.008
Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing
Gurney M, Kundu S, Pandey S, O’Dwyer M.
Front. Immunol., 2022 Feb 11. doi:10.3389/fimmu.2022.802906
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an “Off the Shelf” Therapy for Multiple Myeloma
Stikvoort A, van der Schans J, Sarkar S, Poels R, Ruiter R, Naik J, Yuan H, de Bruijn JD, van de Donk NWCJ, Zweegman S, Themeli M, Groen R, O’Dwyer M, Mutis T.
Hemasphere. 2021 Jun 12;5(7):e596. doi: 10.1097/HS9.0000000000000596
Knockout of CD96 or TIGIT using CRISPR/Cas9 Enhances NK Cell-Induced Cytotoxicity and Cytokine Production in the presence of CD155-Expressing Myeloma Cells
Daly J, Gurney M, O’Dwyer M.
EHA Library. 06/09/21; 325699; EP941
Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
Holthof LC, Stikvoort A, van der Horst HJ, Gelderloos AT, Poels R, Li F, Groen RWJ, Zweegman S, van de Donk NWCJ, O’Dwyer M, Mutis T.
Hemasphere. 2021 Apr 21;5(5):e561. doi:10.1097/HS9.0000000000000561.
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
Gurney M, O’Dwyer M.
Cancers (Basel). 2021 Mar 29;13(7):1568. doi:10.3390/cancers13071568.
Generating natural killer cells for adoptive transfer: expanding horizons
Kundu S, Gurney M, O’Dwyer M.
Cytotherapy. 2021 Jan 8:S1465-3249(20)30966-X. doi:10.1016/j.jcyt.2020.12.002.
CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
Gurney M, Stikvoort A, Nolan E, Kirkham-McCarthy L, Khoruzhenko S, Shivakumar R, Zweegman S, Van de Donk NWCJ, Mutis T, Szegezdi E, Sarkar S, O’Dwyer M.
Haematologica. 2020 Dec 30. doi:10.3324/haematol.2020.271908.
Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways
Teng R, Wang Y, Lv N, Zhang D, Williamson RA, Lei L, Chen P, Lei L, Wang B, Fu J, Liu X, He A, O’Dwyer M, Hu J.
J Immunol Res. 2020 Jun 19;2020:4598476. doi:10.1155/2020/4598476. eCollection 2020.
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide
Sarkar S, Chauhan SKS, Daly J, Natoni A, Fairfield H, Henderson R, Nolan E, Swan D, Hu J, Reagan MR, O’Dwyer M.
Cancer Immunol Immunother. 2020 Mar;69(3):421-434. doi:10.1007/s00262-019-02477-8.
Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer
Daly J, Carlsten M, O’Dwyer M.
Front Immunol. 2019 May 9;10:1047. doi: 10.3389/fimmu.2019.01047. eCollection 2019.
